KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 14 years, with Q4 2025 value amounting to $2.4 billion.

  • Halozyme Therapeutics' Total Non-Current Liabilities rose 4363.48% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 4363.48%. This contributed to the annual value of $2.4 billion for FY2025, which is 4363.48% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Total Non-Current Liabilities of $2.4 billion as of Q4 2025, which was up 4363.48% from $1.6 billion recorded in Q3 2025.
  • Halozyme Therapeutics' Total Non-Current Liabilities' 5-year high stood at $2.4 billion during Q4 2025, with a 5-year trough of $896.2 million in Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Total Non-Current Liabilities averaged around $1.5 billion, with its median value being $1.6 billion (2023).
  • In the last 5 years, Halozyme Therapeutics' Total Non-Current Liabilities surged by 11685.78% in 2021 and then tumbled by 166.47% in 2023.
  • Halozyme Therapeutics' Total Non-Current Liabilities (Quarter) stood at $906.9 million in 2021, then surged by 80.72% to $1.6 billion in 2022, then dropped by 1.66% to $1.6 billion in 2023, then rose by 2.06% to $1.6 billion in 2024, then surged by 43.63% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.6 billion during Q2 2025.